Tidal Investments LLC Buys 1,365 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tidal Investments LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,715 shares of the biopharmaceutical company's stock after acquiring an additional 1,365 shares during the period. Tidal Investments LLC's holdings in Regeneron Pharmaceuticals were worth $5,496,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of REGN. OLD Second National Bank of Aurora grew its holdings in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after buying an additional 15 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares in the last quarter. Manchester Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 18 shares during the period. Finally, Financial Perspectives Inc lifted its stake in Regeneron Pharmaceuticals by 10.9% in the 4th quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock worth $137,000 after purchasing an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 1.4%

REGN stock traded down $8.51 during midday trading on Monday, hitting $588.34. The company had a trading volume of 655,734 shares, compared to its average volume of 801,377. The stock has a market cap of $63.52 billion, a price-to-earnings ratio of 15.37, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock's 50 day moving average price is $592.38 and its 200 day moving average price is $673.91.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.55 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on REGN shares. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday, March 31st. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Finally, Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.